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they comprehensively assessed hepatic and cardiac haemody-
namics and C-reactive protein (CRP) to analyse their interrela-
tionship and to explore their prognostic relevance, in a cohort
of cirrhotic patients. Cirrhosis has for many decades been
classified into two main prognostic stages: compensated and
decompensated stage. Decompensation is characterized by the
presence of clinically evident decompensating events, with
ascites and complications, such as spontaneous bacterial peri-
tonitis, hepatorenal syndrome and variceal haemorrhage being
the most frequent events, while hepatic encephalopathy and
jaundice occur less frequently.2 Development of decompensated
cirrhosis is a milestone, as median survival is significantly lower
in decompensated patients, especially in patientswithmore than
one decompensating event, irrespective of the type of event.2
Portal hypertension is responsible for the majority of decom-
pensating events. Hepatic venous pressure gradient (HVPG) val-
ues >5 mmHg indicate postsinusoidal portal hypertension and
the relationship between HVPG and decompensating events, like
variceal haemorrhage has long been recognized.3 The term clin-
ically significant portal hypertension (CSPH) was defined as a
hepatic venous pressure gradient >10 mmHg in the most recent
Baveno consensus workshop.4 Compensated cirrhosis was fur-
ther divided in the recent AASLD guideline into those with mild
PH (HVPG >5 but <10 mmHg); those with CSPHwithout gastroe-
sophageal varices (GEV) and those with CSPH with GEV.5 This
substaging is prognostically important and the therapeutic
approach is different. However, in clinical practice, invasivemea-
surement of HVPG, although a simple technique, is not available
in every center. Liver stiffness by transient elastography, which is
widely available nowadays, can be used to identify compensated
advanced chronic liver disease,4 and in combinationwith platelet
count to identify up to 40% of patients with compensatedJournal of Hepatology 2
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sophageal varices.6
The ‘peripheral arterial vasodilation hypothesis’ was pro-
posed in 1988 by Schrier et al.7 and is still accepted nowadays.8
Peripheral and splanchnic arterial vasodilation occurs as early
as the compensated stage and is progressive in the decompen-
sated stage and in hepatorenal syndrome, where it is accompa-
nied by activation of vasoconstrictor systems, such as the
renin-angiotensin-aldosterone system, the vasopressin system
and the sympathetic nervous system. Renal sodium and water
retention occurs, because of decreased arterial vascular filling.
Increased cardiac output (CO) is a common feature of cirrhosis.7
Cardiac dysfunction in advanced cirrhosis may contribute to the
decreased effective circulating volume, especially when the
heart fails to compensate for the arterial vasodilation.9 This
may lead to a systolic dysfunction as reflected by a lower CO,
which may precipitate development of hepatorenal syndrome
and early death.
Recently, it has become clear that bacterial translocation, as
well as a storm of pro-inflammatory cytokines, and reactive
oxygen and nitrogen species, in response to pathogen-
associated molecular patterns, appear to be the primary event in
the pathogenesis of decompensated liver cirrhosis and associated
liver failure.10,11 Therefore the syndrome of decompensated
cirrhosis is not solely explained by the peripheral arterial
vasodilation hypothesis, but is a complex interplay between
inflammation and vasodilation, with systemic inflammation
being the primary event in decompensated cirrhosis and associ-
ated organ failure (Fig. 1).11,12 The concept of acute on chronic
liver failure (ACLF) has recently been introduced with clear
diagnostic criteria.13 ACLF is a syndrome distinct from ‘mere’
decompensated cirrhosis, as it is characterized by acute decom-
pensation, the presence of organ failure and associated with a
very high short-term mortality rate. Remarkably, previous epi-
sodes of acute decompensation were absent in 23% of patients
with ACLF, which did not confirm the generally accepted para-
digm that organ failure in cirrhosis is a terminal event that
develops at the latest phase in the course of cirrhosis.13 Inflam-
matory markers, white blood cell count (WBC) and CRP were
significantly higher in patients with ACLF than the group with-
out ACLF, even when patients with infection were excluded


















Fig. 1. The hypothesis of the roles of inflammation, portal hypertension and cardiodynamic state in the pathogenesis of compensated and
decompensated cirrhosis, and acute on chronic liver failure. Question marks represent areas of uncertainty which need further exploration. PAMPs,
pathogen-associated molecular patterns.
EditorialWBC.13 Systemic inflammation, which is already present in
acute decompensation of cirrhosis, appears to be the primary
driver of ACLF and the course of systemic inflammation is asso-
ciated with the course of ACLF.12
Turco et al.1 integrate the acquired knowledge in a compre-
hensive exploratory study of hepatic and systemic hemodynam-
ics, and inflammation by CRP, in a cohort of 238 patients among
the different substages of cirrhosis, assessing their interrelation-
ship and prognostic relevance. The authors adhered to the clas-
sical stages of compensated and decompensated cirrhosis,
although these stages were subdivided into five substages,
according to the recent guidelines, dependent on the presence
and severity of portal hypertension, presence of varices and
decompensation. The novelty of the study was that data were
analysed using different cardiodynamic states defined as hyper-
dynamic, normodynamic and hypodynamic. Thorough hepatic
and cardiac hemodynamic investigations were performed in
patients and CRP was measured as a marker of inflammation.
The main findings are that CRP and a relatively hypo- or hyper-
dynamic circulatory state are, next to known prognostic factors,
predictive of the development of decompensation in compen-
sated cirrhosis and of death or liver transplantation in decom-
pensated cirrhosis. This study contributes to the understanding
of the heterogeneity of cirrhosis and the roles of hepatic and car-
diocirculatory factors and inflammation at the different stages of
cirrhosis, as well as their prognostic relevance.
Many eligibility criteria were applied, significantly impacting
on the number of patients included and the generalisability of
the results. For example, compensated patients who were trea-
ted with non-selective beta-blockers and patients with ACLF or
active infections were excluded from the study. The effect of
disease-modifying treatments, such as use of direct-acting
antivirals, or liver transplantation were adequately accounted888 Journal of Hepatology 2for in the analysis. However, given the number of events per
variable in the study, there is still a risk that the proposed model
could over-fit the data, as rightly discussed by the authors.
Moreover, calibration plots showed some under/overestimation
of the probability of event at the extreme, especially for com-
pensated cirrhosis. Therefore, studies are needed to externally
validate the proposed prognostic models. The authors explain
that the results of their study do not provide insight to the
sequential interaction between bacterial translocation, inflam-
mation and hemodynamic alterations at different stages of cir-
rhosis and that this should be further explored. Indeed, there
is a need for better understanding of the drivers of the different
stages of cirrhosis, in order to identify patients at higher risk of
poor outcome or to predict the response to a given therapy and
move towards individualizing patient care in cirrhosis using
therapies directly targeting the driver.Financial support
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